Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TTNP.pk 0.93$ now... bio play ramping up...
TEC near day high... oil play.. Oil over 59$ now
PLI about to go nutso
PLI loading on news
TEC day hod 0.43$ getting volume now
MCET slowly upmove again
TEC oil play moving up...
SPNG huge gappola... 5 cent around the corner
SPNG a close over 4c would be nice!!!
SPNG eeee. think will run eod and gappola on monday
you lucky man... i'm bidding since weeks @0.0002 but not getting 1 share... but let's see what will happens with this one
EPCG.pk huge volume today fot this stock...
Gold moving up... PRMO and MYNG goldie-stocks
EPCG.pk continuing adding here at this level... insider filed another 5mio yesterday at this price... now he's holding 216mio shares about half of the float... why? somethin sweet need to come... check the filings
EPCG.pk insider bought another 5mio yesterday... now holding 216mio shares... something breeving...check filigs:
http://www.pinksheets.com/edgar/GetFilingPdf?FilingID=6606207
INBG nice buys comming in at 0.0003
TTNP.pk article on www.thestreet.com/story/10501320/...
"If Vanda Pharmaceuticals is able to find a partner [for Fanapt] they would get the same 10% royalty as Titan Pharmaceuticals. Since a 25% royalty is already assigned to Novartis and Titan, the best that Vanda could hope for is to get a 10% royalty in a partnering arrangement. That would leave the partner with 65% of the sales and 100% of the expenses. A very borderline proposition for a partner. "So, if the best that Vanda can hope for is to get the same 10% royalty that Titan already has locked up, you'd have to be an [idiot] to pay 12 times the price for a Vanda share that you can buy a Titan share for."
SPNG eeee allready gappola.... going through 0.03$ at the open
i'm not selling 1 piece under 0.01$... sorry Mr. Brown!
SPNG eeeee tomorrow gappola
first we had buys @ 0.0004,,, then block sell down to 0.0003, now some buys again @0.0003... nice to see volume
NEOM perfekt buy this mornig @0.021
PRMO lotto moved 100% yesterday on 100mio volume.. still no seller today..
EPCG.pk best lotto play if you have some patience... MR John t. Browning loaded 211mio shares in the market ...check filings:
http://www.secform4.com/insider-trading/800401.htm
NEOM loading here
EPCG.pk... this low float micro has a insider that loaded up 211mio shares last few months...why???? some big news will come. check filings...
PLI moving up again after morning dip
INBG no more seller's @ bid???? lotto play ready
INBG
SPNG eeeeeeee
KERX going nutso....
VNDA rocking again today... TTNP.pk lagging... should follow. check news:
Titan Announces FDA Approval of Fanapt (Iloperidone) For the Treatment of Schizophrenia
On Wednesday May 6, 2009, 10:23 pm EDT
Buzz up! Print Related:Titan Pharmaceuticals Inc., Vanda Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Titan Pharmaceuticals, Inc. (Pink Sheets: TTNP - News) today announced that Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA - News) has received U.S. Food and Drug Administration (FDA) approval to market Fanapt™ (iloperidone), an atypical antipsychotic, for the acute treatment of adult patients with schizophrenia, a chronic debilitating disorder which affects more than two million Americans, and millions more worldwide. Global sales from the class of atypical antipsychotics exceeded U.S. $20 billion in 2007.
Related Quotes
Symbol Price Change
TTNP.PK 0.80 +0.03
VNDA 12.24 +0.97
{"s" : "ttnp.pk,vnda","k" : "c10,l10,p20,t10","o" : "","j" : ""} Vanda plans to make Fanapt™ available in pharmacies later this year. Titan is entitled to receive royalties on global net sales of Fanapt™ equal to 8% on annual net sales up to $200 million, and 10% on annual net sales above $200 million. Titan incurs no ongoing expenses associated with this potential future income.
“We congratulate the management and employees of Vanda on their dedication and perseverance in obtaining FDA approval of Fanapt™. This is an important milestone for both Titan and Vanda,” said Sunil Bhonsle, President of Titan. “This medicine will provide an important option to the patients suffering with this debilitating disease.”
SPNG _gieee the gapper tomorrow!!!!
EPCG.pk another micro to watch... insider collected over 211mio shares last few months... something will happens...check F4 filings:
http://www.secform4.com/insider-trading/800401.htm
gold micro's PRMO and MYNG
PRMO now 27 mio..volume...pinki getting slowly some action
PRMO 21mio volume now... getting ready
INBG... market falling.. time for microsss-play's
PRMO.pk gold micro heating up...could be a multibagger
VNDA and TTNP.pk... nice... adding some TTNP more... undervalued in my opinion on this news:
Titan Announces FDA Approval of Fanapt (Iloperidone) For the Treatment of Schizophrenia
On Wednesday May 6, 2009, 10:23 pm EDT
Buzz up! Print Related:Titan Pharmaceuticals Inc., Vanda Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Titan Pharmaceuticals, Inc. (Pink Sheets: TTNP - News) today announced that Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA - News) has received U.S. Food and Drug Administration (FDA) approval to market Fanapt™ (iloperidone), an atypical antipsychotic, for the acute treatment of adult patients with schizophrenia, a chronic debilitating disorder which affects more than two million Americans, and millions more worldwide. Global sales from the class of atypical antipsychotics exceeded U.S. $20 billion in 2007.
Related Quotes
Symbol Price Change
TTNP.PK 0.78 +0.01
VNDA 12.00 +0.73
{"s" : "ttnp.pk,vnda","k" : "c10,l10,p20,t10","o" : "","j" : ""} Vanda plans to make Fanapt™ available in pharmacies later this year. Titan is entitled to receive royalties on global net sales of Fanapt™ equal to 8% on annual net sales up to $200 million, and 10% on annual net sales above $200 million. Titan incurs no ongoing expenses associated with this potential future income.
“We congratulate the management and employees of Vanda on their dedication and perseverance in obtaining FDA approval of Fanapt™. This is an important milestone for both Titan and Vanda,” said Sunil Bhonsle, President of Titan. “This medicine will provide an important option to the patients suffering with this debilitating disease.”